Biopharmaceutical technology is one of the most promising biotechnologies in the world. With the development of modern biotechnology, biopharmaceuticals are thriving and developing rapidly in the world as a high-tech biotechnology industry, bringing unprecedented market prospects to biopharmaceuticals in China and the world. Chinese biopharmaceutical industry is booming and growing up. The national biopharmaceutical industry of China, especially the development and industrialization with genetic engineering drugs as its core fields, has already reached a certain market scale after nearly 20 years of development. The biopharmaceutical industry will be one of the most active economic sectors in China, whereas the biotechnological revolution with modern biopharmaceutical technology has become the lifeblood of maintaining human health and food safety in the future. The study explores the current status, trend, existing problems and development strategies of the biopharmaceutical industry in China. It also probes into Chinese biopharmaceutical industry and its bases.
Introduction
There are two concepts of the composite term "biopharmaceutical industry" in the broad and narrow definitions (Walsh, 2001 ). The broadly defined "biopharmaceutical industry" refers to a class of enterprises or companies engaged in similar business to make products for prevention, treatment, diagnosis, and other uses in pharmacy. The narrowly defined "biopharmaceutical industry" is the biomedical products for the prevention, diagnosis and treatment of human diseases.
In fact, biopharmaceuticals mainly include biochemical drugs, bioengineering drugs and genetic engineering drugs, genetic engineering vaccines, new vaccines, and diagnostic reagents, micro ecological preparations, blood products, and other biological agents. Among them, the most important technology applied in biopharmaceutical industry is genetic engineering technology, which uses cloning technology and tissue culture technology to cut, insert, link and recombine DNA fragments to gain useful biopharmaceutical products. In practice, biopharmaceutical products mainly include three major categories, i.e. genetic engineering drugs, biological vaccines and biological diagnostic agents, that play an important role in the diagnosis, prevention, control and eradication of infectious diseases to protect and extend human health and longevity. ). Therefore, biopharmaceutical industry is booming and half of the world's pharmaceuticals are biosynthesized in modern industry. Particularly, when combining drugs with complex molecular structures, it is not only simpler than chemical synthesis, but also has higher economic benefits. Developing the biomedical products will help humans solve many current diseases that cannot be human, and reform the food production and eliminate human malnutrition. These biomedical products will extend human life and improve people's lives.
The biopharmaceutical technology is a new flourishing industrial technology. Although it started relatively late, it has developed very rapidly and achieved unprecedented results in just a few decades. Since the launch of Human Genome Project, the world-wide public media has continuously drawn a beautiful picture and reveals the genetic mystery of life to the public and global people (Shimaoka and Springer, 2003; Crunkhorn, 2014) . However, genetic information is not directly involved in lives, but indirectly guides the metabolism of the organism by controlling the form of proteins. The genetic information contained in a gene, through a series of complex reactions, eventually leads to the formation of the corresponding protein(s) involved in various activities of life. Therefore, functional genomics and proteomics naturally become hotspots in the biological research fields today. Proteins, the carriers of gene function (especially enzymes involved in metabolism), are the executives of life activities. In the human genome, most of the genes and their functions need to be studied, revealed and elucidated at the protein level. As a result, the development prospects of biopharmaceutical technology are bright with more and more companies engaged in biopharmaceutical industry and relevant technology research, from the previous small-scale decentralized industry to the large-scale centralized large-scale industry. At the same time, some countries have increased their emphasis on biopharmaceutical technology, and these countries invest a large amount each year to encourage companies to develop and innovate. With the strong backing of the country, biopharmaceutical technology is even more powerful. Companies engaged in biopharmaceutical technology are springing up all over the world. The drugs from the biopharmaceutical industry will enter the streets and all over the world soon. Biopharmaceutical industry will become the world's largest industry. It is globally the fastest growing industries that are actually the potential driver of future economic growth (Hsu and Research of biopharmaceutical technology is a strong support for countries in the world to implement national healthy living and development policies. Biopharmaceutical research can develop new drugs that can prevent and treat various diseases, improve human life, improve human living standards and allow humans to longevity. Biopharmaceutical industry is a sunrise industry in China. The biopharmaceutical industry will be the most active and most influential emerging industry in China. It will have an important impact on solving major problems related to human survival and development, such as human health, resources, environment, agriculture and industry.
The development of modern biopharmaceutical industry
The trends and scopes of biopharmaceutical technology in various countries and regions are not uniform. Meanwhile, modern biotechnology has a wide range of practical applications in biopharmaceuticals, environmental protection, food, genetic research, etc., among which biopharmaceutical industry is now the important application of biotechnology. More than 60% of human biotechnology achievements are concentrated in the pharmaceutical industry, to develop new specialty drugs or to improve traditional medicines, which has caused major changes in the pharmaceutical industry, and biopharmaceutical technology has developed rapidly. More than 2,200 biotech drugs have been developed globally, of which more than 1,700 have entered clinical trials (http://s.askci.com/data/year/). The rapid increase in the number of biotech drugs worldwide shows that industrialization of the world medicine in the 21st century is gradually entering the investment harvest period, and the global biopharmaceutical industry is growing rapidly. Since the 1990s, global biopharmaceutical sales have grown at an average annual rate of more than 30%, much higher than other industries with an annual growth rate of less than 10%. The biopharmaceutical industry is rapidly developing into the most promising high-tech pillar industry.
Although the world's first medical biotechnology product has been around for less than 20 years, about 270 million people worldwide have benefited from drugs and vaccines made from biotechnology. Nearly 100 biotech drugs and vaccines have been put on the market to date, and The biopharmaceutical industries in the United States and Europe usually have the following characteristics. First, the merger of companies is common in the development process of biopharmaceutical industries. After the merger, the strength of biopharmaceutical technology companies has grown. For example, two biopharmaceutical companies, Celltech and Shire, have been ranked among the top 100 companies in the UK. The second is to make joint operations with the traditional companies. In the process of struggle for survival and development, more and more emerging biopharmaceutical companies are uniting with traditional pharmaceutical companies.
The third is to frequently increase investment in the scientific research of biopharmaceutical industries. The deciphering of human genes has shown attractive prospects for biopharmaceutical technology and has become the most advanced research project in the biotechnology field. Up to date, there are three genetic cracking research centers in the world, three in the United States and one in the United Kingdom. Fourth, the biopharmaceutical technology companies are gradually maturing. The US and European biopharmaceutical companies that have survived the stock market storms seem to be maturing, and the companies have shown a more stable and closer to the market.
Today, more and more biopharmaceutical companies are targeting the development and promotion of new drugs. Fifth, the investment markets broad in biopharmaceutical industries. In the past 20 years since the birth of the biopharmaceutical industry, 75 drugs, vaccines, and diagnostic tests have passed the certification of FDA (Food and Drug Administration), changing traditional medical practice and producing billions of dollars in sales. There are presently more than 5,000 global biotechnology companies, of which public companies account for about 16% and private companies account for about 84%. Furthermore, more than 2,200 biopharmaceuticals and vaccines have been put on the market, of which more than 1,700 entered clinical trials. The report was commissioned by the consulting firm of Pugatch Consilium of PhRMA, in which they found that different policies in different economies are the main factors affecting BCI scores (PhRMA, 2016). Furthermore, those countries introducing and encouraging innovation were at the forefront of biopharmaceuticals in the report (PhRMA, 2016) . This research report mainly scores BCI from the five major economies in the world, with a score of 100. These five aspects include scientific and technological strength and infrastructure, intellectual property protection, clinical research and framework systems, regulatory systems, market access and funding. Their questionnaires were conducted by senior managers of biopharmaceutical companies in various countries. These senior managers clearly have a deeper understanding of the biopharmaceutical market. Given that emerging market and mature market issues are slightly different, their questionnaires cover 25 questions in five aspects, and the answers to each question are available in four levels. They are ranked based on these answers to the BCI score of each country. 
The biopharmaceutical industry and its development trend in China
The 
The development status of Chinese biopharmaceutical Industry
With the rapid development of Chinese economy, changes in living environment, changes in people's health concepts, and the acceleration of the aging process of the entire society, the biopharmaceutical industry, which is closely related to the quality of human life, has maintained a continuous growth trend in recent years. Up to now, the biopharmaceutical industry has become one of the fastest growing industries in the world, and China, as the world's second largest economy, has also played an important role in the biopharmaceutical industry. The scale of Chinese biopharmaceutical companies continues to increase, and the domestic biopharmaceutical industry is structurally stable and tends to be rationalized.
Comparing the data in recent years, we can find that the sales revenue of Chinese 
Analysis of the development trend of Chinese biopharmaceutical industry
Some developed countries and developing countries have taken the biopharmaceutical industry as the strategic focus of national development, making it an important starting point for leading a new round of economic growth and coping with the current international financial crisis.
As the world's largest developing country and the most promising emerging market, the accelerated biopharmaceutical industry is not only a strategic choice, but also a realistic economic China, and many of them have obtained approvals for trial production or production of genetic engineering drugs, which are distributed throughout the country. In the last decade or so, China has independently developed some new special effects drugs, which have determined the production technology problems of drugs that could not be produced or produced at a particularly expensive cost in the past. These drugs not only can effectively fight against some intractable diseases, but also have great advantages in avoiding side effects.
(1) The integration of companies in Chinese biopharmaceutical industry becomes accelerated.
Compared with the biopharmaceutical companies in the developed countries, Chinese biopharmaceutical companies are relatively small. Most of Chinese pharmaceutical companies lack the ability to innovative products and implement innovative research, and they have not created a true pharmaceutical giant. However, a few domestic Chinese pharmaceutical companies have precipitated their core competitiveness indeed in the development process.
Meanwhile, with the regulation of the industrial environment and fierce competition, the biopharmaceutical companies will intensify the survival of the fittest in China. In order to enhance their competitiveness, these biopharmaceutical companies restructuring and integration process is accelerating. Although the upstream development of Chinese modern biotechnology is good, there are not many applicable products that are transferred from the upstream to the middle. The relevant departments speculate that the product conversion rate does not exceed 0.5%, resulting in a small amount of new drug reserves for downstream companies, and it is difficult to form an echelon of products. China is particularly prominent in this regard, and it is difficult to form an echelon of products. These phenomena are mainly manifested in the following three aspects. Firstly, the key instruments, equipment, and reagents used in research, development, and production are all dependent on imports, and the capital investment is high. Chinese biopharmaceutical industry has high risks, small industrial scale, unsuitable production processes, and low recovery rate, which seriously restricts the industrialization of biopharmaceuticals. Secondly, most of the people engaged in biopharmaceutical development in China are scientists engaged in basic and innovative research, lacking industrial research. Thus, the necessary engineering professionals have greatly restricted the industrialization process. Thirdly, the gap between materials and new production technology development and the world's advanced level is large, and the mid-stream engineering and supporting technical personnel are scarce. Chinese biopharmaceutical companies are too small to form economies of scale to participate in international competition.
In addition, due to imperfect laws and policies related to intellectual property protection in China, the domestic companies pay insufficient attention to intellectual property protection. At the same time, a series of serious human resources problems such as the loss of biopharmaceutical technicians are also common among Chinese biopharmaceutical companies.
The development strategy of Chinese biopharmaceutical industry
(1) Appropriate restructuring strategies should be selected to accelerate the reorganization of pharmaceutical companies and optimize the regional industrial structures according to the characteristics of the enterprises.
In the future market, cross-border integration between industries will continue to increase, mainly because the division between industry and industry will become increasingly blurred, and cooperation between companies will increase. Many companies engaged in the production of medicine, agriculture, environment, and energy are engaged in biotechnology production too. In Changzheng Pharmaceutical Company to achieve a large-scale organizational structure. First, the advanced and mature technologies can help the biopharmaceutical industry to obtain the basic conditions for introducing venture capital with a broad market prospects.
Secondly, biopharmaceuticals have passed the blind end-expiration heat, and the silence gradually entered the stage where it can be viewed more rationally. Third, biopharmaceuticals are closely related to human self-security, and there are inevitably many administrative interventions in the biopharmaceutical industry. Therefore, when biopharmaceuticals are becoming the focus of investors' attention, we need to introduce risk funds in a timely manner to expand the competitive advantages of biopharmaceutical companies.
(5) The intellectual property strategy should be improved in the biopharmaceutical process.
The perfection of the intellectual property protection system is one of the important factors related to the development of innovative drugs. The intellectual property protection system not only protects its own interests, but also respects others' property rights only, and protects its own intellectual property rights from being infringed. It is to give a full play to its own advantages and maximize its own value.
Conclusions and remarks
In summary, Chinese biopharmaceutical industry is booming and growing up. Although attaches importance to develop biotechnology drugs, anti-infection, cardiovascular, digestive system and anti-tumor drugs. Secondly, due to the low level of originality, it is expected that it will be difficult to bring new drugs with great benefits soon, especially the very hot teniposide drugs.
Meanwhile, it is more difficult to resist the foreign similar and same target drug market. Thirdly, the basic characteristics of high-risk, high-input research and development have gradually been accepted by people. Fourthly, the subjective role of innovation in private companies is gradually becoming clear. In addition, Chinese biopharmaceuticals, medical informatization and high-performance medical devices are listed as the country's three promising areas during the 13th
Five-Year Plan period in China. In short, the future development prospects of Chinese biopharmaceutical industry are extremely optimistic.
